The pharmacokinetics of etanercept in healthy volunteers

OBJECTIVE: To describe the pharmacokinetics of etanercept when administered by subcutaneous injection in single doses to healthy volunteers. METHODS: Twenty-six healthy volunteers between 19 and 50 years of age received single doses of etanercept 25 mg by subcutaneous injection into the abdomen. Serial serum samples were collected for 21 days. An enzyme-linked immunosorbent assay with a quantitation limit of 0.3 ng/mL was used to measure the drug concentrations. RESULTS: Etanercept was well tolerated by healthy volunteers. A one-compartment model was found to best describe the concentration-time data and was used to determine the pharmacokinetic parameters. Etanercept is slowly absorbed from the site of injection with a time of peak concentration (+/- SD) of 51 +/- 14 hours; peak concentration was 1.46 +/- 0.72 mg/L. The AUC was 235 +/-98 mg x h/L, apparent clearance was 132 +/- 85 mL/h, apparent volume of distribution was 12 +/- 6 L, and the half-life was 68 +/- 19 hours. CONCLUSIONS: Etanercept was slowly absorbed and slowly eliminated after subcutaneous administration. Dosing at the recommended rate of 25 mg twice weekly would be expected to result in concentrations of approximately 3 mg/L. Intersubject variability for apparent clearance in healthy volunteers was 64%.

This article has been cited by other articles:

				M. A. Mascelli, H. Zhou, R. Sweet, J. Getsy, H. M. Davis, M. Graham, and D. Abernethy Molecular, Biologic, and Pharmacokinetic Properties of Monoclonal Antibodies: Impact of These Parameters on Early Clinical Development J. Clin. Pharmacol., May 1, 2007; 47(5): 553 - 565. [Abstract] [Full Text] [PDF]

				J. Borras-Blasco, C. Nunez-Cornejo, A. Gracia-Perez, J D. Rosique-Robles, M. E. Castera, E. Viosca, and F J. Abad Parapharyngeal Abscess in a Patient Receiving Etanercept Ann. Pharmacother., February 1, 2007; 41(2): 341 - 344. [Abstract] [Full Text] [PDF]

				A. Gaffo, K. G. Saag, and J. R. Curtis Treatment of rheumatoid arthritis Am. J. Health Syst. Pharm., December 15, 2006; 63(24): 2451 - 2465. [Abstract] [Full Text] [PDF]

				E. Shoji-Hosaka, Y. Kobayashi, M. Wakitani, K. Uchida, R. Niwa, K. Nakamura, and K. Shitara Enhanced Fc-Dependent Cellular Cytotoxicity of Fc Fusion Proteins Derived from TNF Receptor II and LFA-3 by Fucose Removal from Asn-Linked Oligosaccharides J. Biochem., December 1, 2006; 140(6): 777 - 783. [Abstract] [Full Text] [PDF]

				I. A. Arenas, S. J. Armstrong, Y. Xu, and S. T. Davidge Tumor Necrosis Factor-{alpha} and Vascular Angiotensin II in Estrogen-Deficient Rats Hypertension, September 1, 2006; 48(3): 497 - 503. [Abstract] [Full Text] [PDF]

				J. T. Sullivan, L. Ni, C. Sheelo, M. Salfi, and P. M. Peloso Bioequivalence of liquid and reconstituted lyophilized etanercept subcutaneous injections. J. Clin. Pharmacol., June 1, 2006; 46(6): 654 - 661. [Abstract] [Full Text] [PDF]

				I. A. Arenas, Y. Xu, and S. T. Davidge Age-associated impairment in vasorelaxation to fluid shear stress in the female vasculature is improved by TNF-{alpha} antagonism Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1259 - H1263. [Abstract] [Full Text] [PDF]

				R. Noguera-Pons, J. Borras-Blasco, I. Romero-Crespo, R. Anton-Torres, A. Navarro-Ruiz, and J. A. Gonzalez-Ferrandez Optic Neuritis with Concurrent Etanercept and Isoniazid Therapy Ann. Pharmacother., December 1, 2005; 39(12): 2131 - 2134. [Abstract] [Full Text] [PDF]

				I. A. Arenas, S. J. Armstrong, Y. Xu, and S. T. Davidge Chronic Tumor Necrosis Factor-{alpha} Inhibition Enhances NO Modulation of Vascular Function in Estrogen-Deficient Rats Hypertension, July 1, 2005; 46(1): 76 - 81. [Abstract] [Full Text] [PDF]

				H. Zhou Clinical Pharmacokinetics of Etanercept: A Fully Humanized Soluble Recombinant Tumor Necrosis Factor Receptor Fusion Protein J. Clin. Pharmacol., May 1, 2005; 45(5): 490 - 497. [Abstract] [Full Text] [PDF]

				D.-S. Yim, H. Zhou, M. Buckwalter, I. Nestorov, C. C. Peck, and H. Lee Population Pharmacokinetic Analysis and Simulation of the Time-Concentration Profile of Etanercept in Pediatric Patients With Juvenile Rheumatoid Arthritis J. Clin. Pharmacol., March 1, 2005; 45(3): 246 - 256. [Abstract] [Full Text] [PDF]

				H. Zhou, V. Parks, A. Patat, F. Le Coz, D. Simcoe, and J. Korth-Bradley Absence of a Clinically Relevant Interaction Between Etanercept and Digoxin J. Clin. Pharmacol., November 1, 2004; 44(11): 1244 - 1251. [Abstract] [Full Text] [PDF]

				N. J. Olsen and C. M. Stein New Drugs for Rheumatoid Arthritis N. Engl. J. Med., May 20, 2004; 350(21): 2167 - 2179. [Full Text] [PDF]

				H. Zhou, A. Patat, V. Parks, M. Buckwalter, D. Metzger, and J. Korth-Bradley Absence of a Pharmacokinetic Interaction between Etanercept and Warfarin J. Clin. Pharmacol., May 1, 2004; 44(5): 543 - 550. [Abstract] [Full Text]